These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 22481233)

  • 1. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
    Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
    J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
    Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
    J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
    World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAZ is an independent prognostic factor in non-small cell lung carcinoma: Elucidation at protein level.
    Malik SA; Khan MS; Dar M; Hussain MU; Mudassar S
    Cancer Biomark; 2017; 18(4):389-395. PubMed ID: 28128737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
    Qiu C; Dong W; Su B; Liu Q; Du J
    J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of nestin expression in resected non-small cell lung cancer.
    Ryuge S; Sato Y; Wang GQ; Matsumoto T; Jiang SX; Katono K; Inoue H; Satoh Y; Masuda N
    Chest; 2011 Apr; 139(4):862-869. PubMed ID: 20829334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
    Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
    Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
    Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
    J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between RGS5 expression and cancer differentiation and metastasis in non-small cell lung cancer.
    Huang G; Song H; Wang R; Han X; Chen L
    J Surg Oncol; 2012 Mar; 105(4):420-4. PubMed ID: 21780128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
    Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
    Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
    Zhang Z; Guo Y
    Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
    Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
    J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
    Urban D; Bar J; Solomon B; Ball D
    J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.